Sandoz Sets Out Expectations For US Humira Competition

Dedicated Q&A With Company Covers US Launch Of Hyrimoz Adalimumab Biosimilar

 
• By Dave Wallace

Acknowledging an “unprecedented” competitive landscape for adalimumab biosimilars in the US, Sandoz has spoken to Generics Bulletin about its expectations for its Hyrimoz rival to Humira.

Company sign reading Sandoz A Novartis Division
Sandoz discusses its recent US adalimumab biosimilar launch • Source: Shutterstock

The start of July has seen a number of new Humira (adalimumab) biosimilars hit the US market, following Amgen’s debut of biosimilar competition at the start of this year. (Also see "Fresh Wave Of Adalimumab Biosimilars Hits US" - Generics Bulletin, 3 July, 2023.)

One of the firms in the running is Sandoz, which has launched its Hyrimoz (adalimumab-adaz) version in a 100mg/ml...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products